MAPT and Alzheimer disease: It should be added that MRI can also support exclusion of patients from tau-targeting clinical trials with confounding pathologies other than probable AD or MCI-AD, e.g., dementia with Lewy bodies, Parkinson’s disease, multiple sclerosis, PSP, hydrocephalus, Huntington’s disease, or prion disorders.